Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma

Table 5

Univariate and multivariate logistic regression analyses exploring factors associated with survival after chemoembolization.

Prognostic factors	Reference	Univariate analysis		Multivariate analysis
		HR (95% CI)	value	HR (95% CI)	value
Age > 65 years	≤65 years	0.92 (0.61–1.4)	0.707
Gender: male	Female	0.80 (0.5–1.27)	0.338
Etiology
HCV	HBV	1.34 (0.83–2.17)	0.229
HBV + HCV		0.40 (0.05–2.87)	0.359
Others		0.82 (0.45–1.49)	0.518
Child–Pugh class B	Class A	1.38 (0.86–2.22)	0.182
AFP level: ≥200 ng/mL	<200 ng/mL	1.26 (0.81–1.96)	0.312
Total bilirubin: >1.0 mg/dL	≤1.0 mg/dL	1.69 (1.11–2.55)	0.013
Albumin: ≤3.5 g/dL	>3.5 g/dL	2.04 (1.32–3.16)	0.001	1.73 (1.11–2.71)	0.016
Platelet count: ≤10^5 mm^3	>10^5	1.03 (0.68–1.56)	0.891
Size of main tumor: >5 cm	≤5 cm	1.90 (1.15–3.14)	0.012
Number of tumors: >5	≤5	2.31 (1.49–3.57)	<0.001	2.06 (1.32–3.23)	0.002
Vascular invasion: present	Absent	5.08 (2.86–9.02)	<0.001	4.59 (2.55–8.27)	<0.001
Grouping: lockdown	Prelockdown	0.88 (0.57–1.35)	0.555
Delayed treatment: >90 days	≤90 days	1.25 (0.77–2.02)	0.365

HR, hazard ratio; CI, confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein.